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The 19th Annual Meeting of the European 
Lipoprotein Club
Anton F.H. Stalenhoef, Katriina Aalto-Setala, Victor W. Armstrong, Pascale Benlian,
Hans Dieplinger, Steve Humphries, Armin Steinmetz
he European Lipoprotein Club met September 9 
to 12, 1996, in Tutzing, Germany. There were 99 
participants from 13 European countries and
the United States.
Dr Jonathan C. Fox from the University of Pennsyl­
vania, Philadelphia, opened the meeting with a state-of- 
the-art lecture entitled “Cardiovascular Gene Therapy: 
Current Concepts.” Gene therapy constitutes a novel 
therapeutic approach to selected cardiovascular diseases 
and is designed to augment traditional techniques of 
diagnosis and treatment by targeting the molecular 
mechanisms of disease.
Dr Fox first presented the general strategies driving 
the development of gene therapy. In the case of delete­
rious gene mutations causing disease, the defective gene 
can be replaced with a normal copy. In a pathophysio­
logic process that can be alleviated through augmented 
gene function, a beneficial gene can be overexpressed or 
a mutated “designer” gene, which is either more active 
or in some way more beneficial than its natural precur­
sor, can be expressed. Normal genes may also confer 
therapeutic benefits by virtue of their expression in a 
novel environment. The expression of harmful genes can 
also be inhibited by antisense oligonucleotides, antisense 
RNA expression vectors, ribozymes, or triplex DNA. 
Dominant negative genes can be expressed, eg, encoding 
a protein that binds to regulatory partners but is not 
active. So-called decoy DNA, made up of short segments 
of double-stranded DNA encoding the recognition se­
quence for regulatory proteins such as transcription
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factors, can be delivered to cells, binding the transcrip­
tion factors and, thereby, competing for their biologic 
targets and inhibiting their function.
The requirements for successful gene therapy are 
fourfold. The first of these is the identification of an 
appropriate molecular target, one that is critical to the 
development or progression of the disease. The second 
is the use of an efficient gene transfer vector system, 
which increasingly takes advantage of unique properties 
of the target cell or tissue. The third requirement is use 
of an effective local delivery approach. Finally, and 
perhaps most important in the final analysis, gene ther­
apy for any disease should confer significant benefit that 
is both safe and long-lasting. These requirements are 
often woven together, in that the choice of molecular 
target implies the cell type or tissue to be treated, and 
these, in turn, dictate the gene transfer vector system 
and local delivery technique to be used. With regard to 
overall efficacy and safety, good animal models are 
critical to designing and testing potential therapies.
Dr Fox described many vector systems used today. 
Unfortunately, none of the present systems are flawless, 
and each has some unique advantages and disadvan­
tages. Plasmid DNA (either naked or in liposomes) have 
been used in some of the earliest in vivo gene transfer 
experiments. Plasmid D N A  uptake is through inefficient, 
nonspecific mechanisms, and chromosomal integration, 
which can only occur in dividing cells and is required for 
persistent activity, occurs at random sites in the target 
genome, implying the risk of insertional mutagenesis. 
The advantages of plasmid DNA include low toxicity, 
ease of preparation, and absent inflammatory reaction. 
Because of low efficiency and the need for a dividing 
target cell, this vector system has been largely aban­
doned. An exception is the use of plasmid DNA gene 
transfer of vascular endothelial cell growth factor for 
arterial insufficiency in peripheral vascular disease, the 
objective of a phase I clinical trial in the United States. 
Retroviruses are more efficient gene transfer vectors 
than plasmid DNA, but the integration, which is re­
quired for transgene expression and also depends on 
target cell division, also occurs at random in the target 
cell genome, risking insertional mutagenesis as well. 
Retroviruses infect a wide range of cells, and the expres­
sion is stable for months and declines slowly. Their 
disadvantages include technically difficult preparation, 
that their integration requires cell division, and that the 
potential to recombine with viral elements in the envi­
ronment poses the theoretic risk of malignant transfer-
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ER = endoplasmic reticulum 
FCH =  familial combined hyperlipidemia 
HSPG =  heparan sulfate proteoglycan
LRP LDL receptor-related protein
NEFA =  nonesterihed fatty acid 
N ID D M  =  noninsulin dependent diabetes mellitus 
OVR =  oocyte receptor model 
PDGF =  platelet-derived growth factor 
RAP =  receptor-associated protein
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mation. Retrovirus has been used in a clinical trial for 
familial hypercholesterolemia. The protocol was quite 
complex, and thus far, only marginal effects on LDL 
cholesterol level have been achieved. Adenoviruses have 
a broad host range and gene transfer is highly efficient. 
They remain episomal, posing a low risk of insertional 
mutagenesis. One of the biggest problems with adeno­
viruses is the immune response. This limits the persis­
tence of expression to about 2 weeks, and there is a 
potential risk for immuno-mediated host injury. Other 
viruses being developed for use in gene therapy experi­
ments include adeno-associated virus, herpes simplex, 
SV-40, vaccinia, sindbis, and lenti viruses such as human 
immunodeficiency virus (HIV). Semisynthetic vectors 
are also under development that attempt to combine the 
cell entry advantages of viral coat proteins with the 
simplicity of plasmid DNA vectors.
Ex vivo gene therapy means that autologous cells are 
removed and transduced in cell culture. This technique 
is useful only in selected situations, but in most cases, 
this method has just been proof of the principle that 
gene transfer can be achieved. In vivo gene transfer is 
the goal on which gene therapeutic techniques will be 
based in the future. interest mar
delivered locally, either through direct tissue injection or 
percutaneous vascular delivery. The gene of interest 
might also be delivered svstemicallv and the vectory y  
tissue-specific cellular uptake
msms or gene expression 
In cardiovascular diseases, gene therapy techniques
disorders, vascular diseases,are in
■'vises.myocardial diseases, and 
Familial hypercholesterolemia was the first cardiovascu­
lar disorder for which gene therapy has been attempted. 
The advantages of gene therapy for this condition is that 
it is caused by a single gene mutation and there are good 
animal models for the disease. Both retro- and adeno­
virus vectors have been used in experiments with these 
animal models. Restenosis is another major clinical
problem that is targeted for gene therapy in
cardiovascular diseases. Smooth muscle cell prolifera­
tion has been identified as a major contributing event in 
the development of restenosis, and growth factors, tran­
scription factors, and cell cvcle mediators are
in gene tnerapy approacnes to tins pr 
Dr Fox concluded his talk with a view of the future of 
gene therapy. Vector development and gene delivery are 
major areas of research at the moment, and much effort 
is directed toward improved gene transfer technologies. 
Better knowledge of molecular pathology is also neces­
sary, and rapid advances in our knowledge of molecular
is ; incorpori into gene therapy ap-
proaches. The design of clinical trials for gene therapy 
should appropriately focus on the safety of these meth­
ods, even before efficacy can be demonstrated. Finally, 
for gene therapy to become a clinical reality, the safety, 
efficacy, and costs of these new techniques will need to 
be compared with those of both traditional and other 
novel therapies for gene therapy to provide meaningful 
benefits for society as a whole.
The major topic of this year’s meeting was “Genetics 
of Lipoprotein 
given by Dr Steve Humphries (London) who outlined 
genetic strategies to identify candidate genes and poten­
tial functional mutations. It is widely accepted that 
differences in plasma lipid levels in individuals in 
general population are determined by variation at a 
number of different genes, interacting with environmen­
tal factors. Any study attempting to identify candidate 
genes must, therefore, U
overview -e was
of genetic heterogeneity and of gene-gene and gene-
environment interactions. The usual strategy to identity 
genes involved in determining a rare inborn error of 
metabolism has been to on a
families that are as large as possible. However, for a 
multifactorial disorder, such a strategy increases the 
chance of individuals carrying other common mutations 
that affect the trait “marrying in,” which, 
results in more confusion than clarification. As such, this 
approach for common polygenic hyperlipidemia is un­
likely to be useful, although it should be useful for rare 
disorders of lipoprotein metabolism such as Tangier 
disease. However, genetic heterogeneity will also con­
found a linkage approach in families, if, for example, 
such an approach had been used to study families with 
dominantly inherited levels of elevated plasma choles­
terol, in some families the mutation would be caused by
T w '
a defect in the LDL-receptor gene, whereas in others the
in gene, and a
approach using only one of these markers would be 
confounded. The strategy of using sibling pairs is a much
stronger approach tor a multitactonal disorder of late 
onset; however, parents may be unavailable because of 
early death, and children may not be useful because they 
have not yet developed the phenotype. The approach is 
to collect pairs of siblings who are both affected (eg, 
hyperlipidemia) and using either random markers or a 
candidate gene to see if the affected siblings share alleles 
at the locus more often than expected by chance alone. 
The statistics for this technique are well worked out, and 
the approach is robust to genetic heterogeneity, A more 
powerful way of using siblings is to use a quantitative
as plasma levels of triglycerides or of an 
apoprotein and to look at the between-siblings differ­
ence in siblings who share (1, 1, or 2 alleles identical by 
state. If the mean difference for a group of siblings is 
smaller in those sharing two compared with those shar­
ing 0 alleles, this is strong evidence for involvement of 
variation at the gene locus in determining the trait.
Although studies using siblings are extremely useful, a 
great deal of progress in dissecting the genetic basis of 
hyperlipidemia has already been made using samples of 
unrelated individuals. There are two basic strategies,
trait s
” or a “bottom-up” approach. The 
top-down approach is when individuals are selected by
e (eg, patients versus he;
at a particular a
•ols), and the
ate gene
2318 Arteriosclerosis, Thrombosis, and Vascular Biology Voi 17, No 11 November 1997
compared between the two groups. Although this ap­
proach is relatively easy and has been used in a number 
of studies, it is not very powerful and can be easily 
confounded by ethnic mix and stratification. A  great deal 
of the apparent inconsistencies in the literature can be 
explained by this problem, with some studies showing an 
association and others not. A more powerful approach is 
the bottom-up strategy, when individuals are genotyped 
at a particular locus, and then the phenotype (eg, plasma 
lipid levels) of those with different genotypes is com­
pared. Although this strategy is more robust to ethnic 
differences, it will be confounded by gene-environment 
interaction. If the effect on plasma lipid traits associated 
with a particular mutation is much larger, for example, in 
men compared with women, in nonsmokers compared 
with smokers, in patients compared with healthy individ­
uals, or in obese individuals compared with lean individ­
uals, then the power of a particular sample to detect a 
statistically significant association will depend crucially 
on the relative proportions of these different subgroups 
of individuals. Because a priori these gene-environment 
interactions are unknown, the apparent inconsistencies 
between published association studies are most likely the 
result of this problem, and study designs using homoge­
neous and clearly defined individuals are ideal. Most 
polymorphisms are themselves unlikely to be of func­
tional significance, but they may be acting as a marker 
for a functional mutation elsewhere at the gene locus. 
The first polymorphism in an apoprotein gene to be 
published is a very good example of this. The Sstl 
polymorphism originally detected by Southern blotting 
using an apoAI gene probe, but which is actually in the 
3' untranslated region of the apoCIII gene, was first 
reported more than 13 years ago (Rees et al, Lancet 
1983;1:444-446). This polymorphism is associated with 
hypertriglyceridemia both in top-down and bottom-up 
studies, and this association has been consistently re­
ported in many different studies. There are more than 50 
publications looking at the relationship between poly­
morphisms in the apoAI-CIII-AIV gene cluster and 
different plasma lipid traits, and it is curious and disap­
pointing that so far the mechanism of this association 
has yet to be determined. Although it has been reported 
that the Sstl site might be a marker for functional 
mutations in the insulin responsive element between the 
apoCIII and apoAIV genes (Li et al, ./ Clin Invest. 
1995;96:2601-2605), a recent paper concluded that, of all 
the polymorphisms in the gene cluster including those in 
the insulin responsive element, the Sstl was associated 
with the greatest effect on plasma lipids (Surguchov et al, 
Arterioscler Thromb Vase Biol. 1996;16:941-947). One of 
the interesting features of polymorphisms in this gene 
region is that they appear to be associated with a greater 
effect on lipid levels in hypertriglyceridemic individuals 
than in healthy controls, and an example of this using a 
neutral polymorphism in exon 3 of the apoCIII gene 
(C1.100-T) was presented.
Clearly, understanding the molecular mechanism of 
this gene-environment interaction would be of great 
relevance. As further examples of these interactions, the 
lipoprotein lipase gene is very informative, and several 
amino acid mutations have been reported in the gene 
that are relatively common (D9N and N291S). Both of 
these mutations, which are present in 2% to 4% of the
cause elevated plasma triglycerides and lower HDL, 
although the effects are relatively moderate. However, in 
individuals who are lean, the effect of these mutations is 
negligible, whereas in those who are obese (eg, body 
mass index>26 kg/m2), the triglyceride-raising and 
HDL-lowering effect of the mutations is much greater. 
From a statistical point of view, this gene-environment
interaction effect is significant and has been shown in 
several studies. Although the mechanism of this effect is 
not yet fully understood, it does give a clear example of 
how knowing an individual’s genotype will only be of 
importance if the environment in which the genotype is 
found is also known, in this case, degree of obesity.
Dr H. Wittrup (Copenhagen) reported on the study of 
the Ser291Asn mutation of lipoprotein lipase in a gen­
eral population cohort of 9214 individuals (The Copen­
hagen City Heart Study) and in a group of 94S patients 
with ischemic heart disease. The mutation was found in 
452 heterozygotes and in 7 homozygotes. The mutation 
was associated with increased plasma triglycerides 
(+.22 mmol/L; 95% confidence interval, .0S-.38) and 
decreased apoAI levels and HDL (- .1 7  mmol/L; 95% 
confidence interval, .12-.23). In contrast with the 
Glyl88Glu mutation which is associated with familial 
chylomicronemia in homozygotes, a phenotype of only 
mild dyslipidemia was observed in homozygotes with the 
Ser291 mutation. On multiple logistic regression analy­
sis, the Ser291Asn mutation was an independent predic­
tor for ischemic heart disease (odds ratio, 1.4; 95% 
confidence interval, 1.05-1.87) in females, whereas this 
was not the case in men. Therefore, common mutations 
that partially disrupt LPL activity were confirmed as a 
cause of an altered lipoprotein profile in the general 
population and may predispose to atherosclerosis.
Dr D. Freeman (Durham) reported data of a sibling- 
pair analysis in normolipidemic families from the United 
States, examining the genetic predisposition to interin­
dividual variations in plasma LDL cholesterol. Although 
50% of the interindividual variation in LDL cholesterol 
was attributed to genetic factors, major candidate genes 
(LDL receptor, apoB, LPL, hepatic lipase) were found 
to have a negligible contribution (<1%). However, the 
predicted effect of the apoE polymorphism on apoB and 
LDL cholesterol levels was found. It was concluded that 
in normolipidemic individuals, apart from the known 
effects of apoE, the genetic contribution to the variation 
in plasma LDL cholesterol does not depend on these
M.-C. Blatter Garin and (Geneva)
general population in countries in Europe,
reported on the effect of sequence polymorphisms in the 
paraoxonase gene and on the risk of developing coro­
nary heart disease in diabetics. They had previously 
demonstrated that the Gln l92Arg polymorphism, which 
alters activity, is associated with an increased risk for 
heart disease in diabetics, and a second polymorphism 
(Leu55Met) was now studied. No difference in lipopro­
tein profile was observed, but the polymorphism was 
associated with highly significant differences in paraoxo­
nase serum concentrations and with increased risk of 
heart disease. However, a strong linkage disequilibrium 
was noted between Glnl92Arg- and Lcu55Met poly­
morphisms, suggesting that the relationship between the 
Leu55Met polymorphism and heart disease may be a 
consequence of this association.
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Dr P. Talmud (London) reported a study of the 
-93T/G transition in the promoter of the LPL gene. The 
carrier frequency of the G allele was .03 in 1521 healthy 
Caucasians and .08 in 230 patients with FCH and 
myocardial infarction. In healthy Afro-Caribbeans, the 
frequency of the G allele was strikingly increased to .63. 
In addition, the G allele was found in strong allelic 
association with the N allele of the Asp9Asn (D9N) 
variant in Caucasians, all carriers of the N9 allele also 
being carriers of the -93G allele. Despite the raising 
effect of the N9 allele on triglycerides, their concentra­
tion was lower in carriers of the -93G allele alone. To 
assess the functional effect of the -93G allele, in vitro 
studies were conducted in a smooth muscle cell line, 
A.10. The -93G allele resulted in a 24% increase in
•  <promoter activity ; n o to bind a
nuclear protein, resulting in a band shift that was not 
observed with the T allele. These results suggest that the 
change in promoter activity associated with the -93G 
allele may be caused by specific interactions with some 
nuclear factors. This, in turn, may account for the lower 
triglyceride levels observed in carriers of this promoter 
mutation.
Dr S. Haubenwallner (Wien) studied the regulation of 
the transcription of apoCIII in HepG2 cells at two 
closely related promoter sites recognized by peroxisome 
proliferation activated receptors and by HNF4, respec­
tively. When cells were incubated with fibrates or ETYA 
or cotransfected with peroxisome proliferation activated 
receptor, this resulted in reduction of the of
apoCIII expression. This effect was abolished when the 
site recognized by HNF4 was mutated, whereas it was 
unchanged when the cells were transfected with a dom­
inant negative I-INF4 mutant. These data suggest that 
the down-regulation of apoCIII induced by peroxisome 
proliferation activated receptors in HepG2 is mediated 
through interactions of peroxisome pr
vated receptor with the HNF4 recognition site.
Dr S. Ries (Regensburg) presented the characteriza-
tion of the promoter of the lysomal lipase in
macrophages and CHO- and HepG2 cells. Within 500 
base pairs upstream of the transaction start site, 
ments recognized by Spl, AP2, as well as macrophage 
specific transcription factors were identified. Neither a 
TATA box nor a CAT box was identified upstream of 
the LAL gene.
A number of talks described functional tests that 
detected protein variation. Dr S. Vilaro (Spain) looked 
at a number of missense mutations in the LPL gene from 
type I hyperlipidemic patients that all had a major effect 
in causing intracellular retention of the mutated protein. 
The mutant N43A prevents A/-glycosylation at the aspar­
agine 43 of the LPL molecule, and the mutant protein 
was totally retained in the rough endoplasmic reticulum 
(ER) of transfected cells. The retention of this nongly- 
cosolated LPL gene induced morphologic changes in the 
ER that could also affect the intracellular transport of
21' nonrek p r 11 • mutations G142E and
S172C produced nonactive proteins that were also re­
tained inside the cells, and in immiinoduorescence and 
eleetromieroscopie studies, mutated proteins were re­
tained and degraded in the lysosomes of transfected 
COS cells. It is of interest that, based on the three- 
dimensional structure of LPL that has been deduced by 
comparison with the pancreatic lipase, these two muta-
varu in
tions both occur within a very tightly packed region 
inside the catalytic domain of the protein. The findings 
suggest that intracellular mis-sorting might be a mecha­
nism of cell quality control of secreted LPL.
Dr F. Benhizia (London) reported on work expressing 
the three known apoB signal 
McArdle RH-7777 cells. In the general population, the 
most common allele of the signal peptide contains 27 
amino acids (SP27), whereas about 30% of chromo­
somes lack three hydrophobic amino acids from the core 
of the protein (SP24). A further variant that has been 
found only in Mexican/Americans has an insertion of 
two hydrophobic amino acids (SP29). In association 
studies, the SP24 allele has been found to be associated 
with lower plasma triglycerides, especially when individ­
uals are on a high-fat diet. In studies originally published 
in 1995, the signal peptide variants had been used to 
drive secretion of the enzyme invertase in a yeast system, 
and this work had shown that compared with SP27, SP24 
and SP29 were retained inside the cell and did not reach 
the medium. To confirm this in a homologous system, 
the three signal peptides had been joined to apoB17, and 
sir transient expression followed in the rat hepatoma 
cells. The results demonstrated that equal amounts of
three variants, andmRNA were
although apoB17 could be seen inside the cells from all 
three variants, SP24 and SP29 proteins remained within 
the cell and were apparently degraded, whereas the 
SP27-directed protein appeared in the medium. These 
results confirm the functional difference of the three SP 
variants and support the hypothesis that apoB signal
variation is directly involved in determining
Dr A. Gruber (Innsbruck) reported on the relation­
ship between apo(a) and ealnexin in the ER 
the hypothesis that the inverse correlation 
plasma concentration of Lp(a) and the length of the 
apo(a) protein might be the result of posttranslational 
mechanisms during apo(a) secretion. In stably trans­
fected HepG2 cells, apo(a) is synthesized as a precursor 
with low molecular weight in the ER. This precursor is 
retained for an unusually long time while processing to 
the mature form occurs, which is found exclusively in the
omparing apo(a) iso forms of different sizes, 
larger allelic variants have longer retention times in the 
ER than smaller ones, and this lonuer residence time is
the result of an increased time for
correct folding and glycosyiation. Calnexin is a predom­
inant integral membrane protein of the ER and associ­
ates transiently with incompletely (bided glycoproteins. 
It, therefore, may be important in apo(a) maturation 
within the cell; this hypothesis was confirmed using a 
calnexin antibody, the results of which showed that the 
important molecular chaperone effects of calnexin are 
crucially involved in causing variable retention times in 
different apo(a) isoforms.
Dr T. Bruin (Amsterdam) used molecular modeling 
and site-directed mutagenesis to study LPL structure 
and function. The amino acid sequence around PI57 is a 
hydrophobic cavity and is highly conserved in both LPL 
and pancreatic lipase (PL); conformation of this cavity is 
stabilized by a conserved network of interactions be­
tween ct and [i strands. It was noted that in rat pancreatic 
lipase that the equivalent of PI57 is replaced by alanine, 
but in human LPL this substitution produced a nonfunc-
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tional protein. However, in rat pancreatic lipase, this 
substitution is accompanied by substitutions in the a  4 
helix (A-V) and in the 0 8 strand (V-A). To explore this 
further, the A137V and V181A substitutions were made 
in wild-type LPL in combination with the P157A. After 
expression of mutants in COS cells, results showed that, 
although neither flanking mutation alone could rescue 
the deleterious effect of AI57, when both were present, 
the catalytic activity of LPL was partially restored. 
Interestingly, the substitution of A137V in wild-type 
LPL gave a 1.6-fold increase in specific activity, indicat­
ing that this substitution is beneficial to the LPL protein. 
The possibility of using such mutations to create “super” 
LPL enzymes was discussed.
Dr D. Gaffney (Glasgow) reported on the detection 
and characterization of two mutations in the apoB gene 
and their effects on LDL levels. The mutations were
A3371V and Q3405E, which were found in 1 and 10,
respectively, of roughly 900 hyperlipidemic individuals 
who were screened. The effect of these mutations on 
LDL structure and binding to the LDL receptor were 
examined using the U937 growth assay. As a compari­
son, patients with the R3500Q, R3500W, and R3531C 
were also included in the assay. LDL from patients with 
3500Q or 3500W both showed a significantly reduced 
ability to support U937 growth, both being about 60% of 
normal LDL. LDL from patients with the 3531C muta­
tion showed a smaller reduction (about 80% of normal 
level), whereas individuals with the 3405E showed about 
90%. The results for two related 3371V individuals were 
unclear, possibly because of high triglyceride levels in 
the proband. Therefore, although the 3405E mutation 
appears to be relatively common in patients from Glas­
gow, it has, at best, a modest effect on LDL function and 
is, therefore, unlikely to have a major impact in deter­
mining plasma lipid levels.
Dr A. Tilkorn (Hamburg) reported studies looking at 
the effect of induced mutations in LAL in determining 
its substrate specificity, using an in vitro expression 
system. Full-length cDNA for LAL was cloned in the 
baculo virus vector using the signal sequence of alkaline 
phosphatase to mediate enzyme secretion into the cul­
ture supernatant and a carboxyl terminal polyhistidine 
tag to allow an efficient single-step purification. A sys­
tematic replacement of six cysteine residues by alanine 
showed that several C-A replacements were silent in
receptor defects (null < was almost 2
their whereas a C234A charge an
enzyme with a marked increase in triglyceride hydrolysis. 
By contrast, cholesterol oleate hydrolysis was severely 
attenuated in this mutant, indicating an important role 
of C234 in substrate specificity. Other studies are under­
way to further characterize the structure and function of 
LAL to determine its role in lipid accumulation states, 
such as foam cell formation and advanced 
rotic lesions.
Dr P. Nichols (Belfast) reported a study in which 19 
LDL receptor mutations have been identified using 
DGGE in familial hypercholesterolemia 
Northern Ireland. As expected from a genetically het­
erogeneous population, no single mutation was com­
mon, although mutations in exon 3, 4, 6, and 10 ex­
plained familial hypercholesterolemia in 30% of the 
patients studied. The most frequent mutation was 932dA 
in exon 67 (n=6) and D461N in exon 10 (n=6). The total 
serum cholesterol in probands for families with class I
m
higher compared with families with class 2 (transport) or 
class 5 (recycling) receptor defects, and this difference 
was highly statistically significant.
The last section of this session focused on exploring 
novel mechanisms of lipoprotein metabolism using ge­
netic tools. Dr W. Drobnik (Regensburg) presented 
biochemical evidence that the genetic defect in Tangier 
disease is associated with changes in the metabolism and 
signaling function of sphingolipids. In fibroblasts of 
Tangier patients, HDL3-mediated efflux of newly syn­
thesized cholesterol, sphingomyelin, and phosphatidyl­
choline is markedly reduced. This is associated with an 
impaired HDL3-induced activation of the PI-PLC sig­
naling pathway in these cells and, in confirmation of this
kinase C activation, was to norm;
I-IDL3-mediated cholesterol and phospholipid efflux. In 
a second study, ceramide as well as sphingomyelin were 
found to be increased by 100 and 40%, respectively, in 
Tangier fibroblasts. In agreement with the known ability 
of ceramide to modulate cell proliferation, Tangier 
fibroblasts showed a 50% reduction in their in vitro 
growth rate, more than twofold greater percentage of 
cells in the G2/M phase, and a reduced number of cells 
in the S phase of the cell cycle. Increased ceramide and 
sphingomyelin content in Tangier fibroblasts was also 
associated with an impaired transport of sphingomyelin 
and glycosylceramide from Golgi to the plasma mem­
brane. Thus, a defect in Golgi transport may result in an 
accumulation of sphingolipids, such as ceramide, which 
act as intracellular messengers and modulate cell func­
tion. Disturbed sphingolipid transport from the Golgi to 
the plasma membrane may also influence lipid compo­
sition of special membrane domains, eg, caveolae, which 
are known to be involved in HDL3-mediated efflux and 
represent centers of signal transduction, therefore, tying 
up the impaired HDL3-induced lipid efflux and phos- 
phoinositol-phospholipase C activation with disturbed 
sphingolipid metabolism and transport. Taken together, 
the biochemical data strongly link the genetic defect in 
Tangier disease with sphingomyelin metabolism.
Dr B. repor on studies of
patients with familial hypertriglyceridemia, looking at 
bile acid malabsorption that resulted in increased bile
arance of plasmaand
low-density lipoprotein. Only some patients with familial 
hypertriglyceridemia show increased bile acid produc­
tion, and this appears to be mainly caused by a failure of 
bile acid absorption from the distal ileum. However, as a 
result of their increased production, their bile pool si/.e 
and secretion rate of bile acids are normal. Such patients 
have markedly higher fractional catabolic rates of LDL 
particles compared with patients with normal bile acid 
production. The study suggests that the increased bile 
acid production and subsequent VLDL overproduction, 
concomitant with an increased hepatic LDL receptor 
expression, lead to stimulated LDL metabolism and, 
therefore, lower levels of LDL. A candidate gene in­
volved in this process is the recently cloned ileal bile acid 
transport protein, and studies of the possibility of muta­
tions in this gene will be of interest.
Dr W. Hofman (Gratz) presented work on transgenic 
mice in which LPL expression has been knocked-out in 
adipose tissue and skeletal muscle, but in which, using a 
cardiac-specific promoter, expression occurs exclusively
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in heart tissue. Of major interest is that in these animals, 
plasma triglyceride levels were almost normal, whereas
mice in which the LPL gene is completely deficient die 
within a few hours of birth as a result of massive 
hypertriglyceridemia. This suggests a potent role of 
cardiac LPL in the clearance of plasma triglyceride-rich 
lipoproteins. The mice expressing LPL exclusively in the 
heart develop normally with regard to body weight and 
composition. However, total essential acids in
smooth muscle cells and adipose tissue were decreased 
more than 80%. The lack of LPL in
apparently causes the inability of the cells to take up 
dietary fatty acids from triglyceride-rich 
The small amounts of essential fatty acids found in these 
noncardiac tissues could originate from two potential 
sources; one possibility that was raised was that LPL 
from cardiac tissue might be transported in the blood to 
muscle or adipose tissue, although this seems unlikely, 
because LPL activity in whole muscle or in 
tissue from these mice was extremely low. The alterna­
tive possibility was that free fatty acids released from 
LPL action in the heart could pass through the circula­
tion and be absorbed by the other tissues.
Dr P. Benlian (Paris) continued the discussion about 
the effect of LPL deficiency by looking at patients with 
type I hyperlipidemia. Current dogma is that such 
individuals are at reduced risk of developing coronary 
atherosclerosis because, although plasma levels of chy­
lomicrons and VLDL are high, these lipoproteins are 
too large to enter the artery wall, and because LPL 
metabolism of these lipoproteins is absent, levels of LDL 
are extremely low. However, to challenge this dogma, 
four type I patients were presented who had developed
decade. The
patients showed evidence of angina and stenosis of the 
coronaiy arteries on angiography, and one individual 
died of a myocardial infarction. Two of the patients were 
smokers and two were not, although other known risk 
factors were not obvious. Interestingly, levels of Lp(a) 
were low in all of these patients. The mechanism of the 
potential atherogenic processes in type I patients was 
discussed, and possibilities include lipoprotein retention 
in the arterial wall, oxidation of the triglyceride-rich 
lipoproteins, or activation of the 
Other patients with type 1 hyperlipidemia (either apo-
some of whom 
had survived to old age without developing atheroscle­
rosis or who had no evidence of premature disease on
in o r
-  o r were
Dr F. de Man (Leiden) described a novel assay to look
of apoE mutations on the binding and
VLDL by aran sulfate
(HSPG)-bound lipoprotein lipase. During lipolysis by
LPL, oteins interact with vessel wall
apoE is considered to
lipoprotein 
VLDL from
complex. It is, therefore, possible that 
ects with apoE mutations may show
and, as a conse-
by
of free fatty acid release from VLDL in
plates. Compared with con
qui
HSPG-LPL coi
VLDL-E3, lipolysis of VLDL-E2 was reduced to 8(.)% 
and lipolysis of VLDL from individuals carrying the E2 
Lys'146-Gln and apoE3-Leiden was reduced to approxi­
mately 60%. This impaired lipolysis was most probably
caused by diminished binding of the particles to HSPG- 
bound LPL, as confirmed by competitive binding studies 
with 125I-labeled control VLDL. It is, therefore, possible 
that the increased risk for coronary artery disease in 
patients with apoE mutations is partly because of a 
defect of their VLDL and VLDL remnants to bind
HSPG-bound LPL.
Dr M. Iiofker (Leiden) presented work to explore the 
potential role of apoCl in lipoprotein metabolism using 
transgenic mice. ApoCl has been reported to activate 
leeithin-cholesterol acyltransferase in vitro and to inhibit
ited receptor binding of lipoproteins. Knock­
out of the ApoCl gene leads to a mild hypereholester- 
olemic phenotype during high-fat feeding, and ApoCl 
overexpression leads to a moderate increase in plasma
The ApoCl transgene contained a contigu- 
DNA fragment encompassing ApoCl and 
the downstream located hepatic control region. How­
ever, on a diet containing sucrose, plasma cholesterol 
levels, particularly plasma triglyceride levels, became 
markedly elevated. Turnover studies show that produc­
tion of VLDL in these animals is within the normal 
range and the lipolysis of VLDL is also normal, suggest­
ing that the process that is affected must be uptake of the
o fVLDL remnants.
ApoCl causes a reduction of VLDL clearance, which is 
most pronounced in male mice. After the liver has been 
excluded from the circulation, the VLDL removal is 
similar in transgenic and non transgenic mice, indicating 
that ApoCl overexpression does not affect the periph­
eral lipoprotein metabolism and primarily modifies the 
liver-mediated VLDL clearance. VLDL can be removed 
by the liver either by LDL receptor- or LRP-mediatcd
mice in which the LDL receptor gene has
elevated over wild-type litter mains, but when crossed 
with the ApoCl-overexpressing mice, both plasma cho­
lesterol and plasma triglycerides are extremely elevated 
(Jong, et al. J Clin Invest. 1996;98:2259 
results suggest that in the LDL receptor knock-out mice, 
in which normally VLDL is cleared by the LRP, the 
ApoCl overexpression blocks LRP-mediatcd uptake. To
s, an adenovirus vector containing a construct 
leading to transient overexpression of 
associated protein (RAP) was used. Overexpression of 
RAP in the LDL receptor knock-out mouse produced a 
moderate increase in plasma lipids only, 
that VLDL clearance is carried out 
med iated processes.
Dr K. Willems van Dijk (Leiden) examined the mech 
anism of apoE3-Leiden and apoE
mice ;
gene transfer. Animals in which the apoE2 gene lias 
been knocked-out develop severe hypercholesterolemia, 
and it was now shown that apoE3-Leiden can rescue this
, whereas crossing with a mouse transgenic for
in major reduction in 
cholesterol levels. VLDL apoE3-Leiden shows
the LDL receptor on I IcpC*2 cells compared
ís not
with VLDL from wild-type mice, whereas VLDL apoE2
ing that is almost as low as that from the 
knock-out mouse. The possibility that LRP can 
function as a back-up lor removal of lipoproteins that 
cannot bind to the LDL receptor was investigated using 
adenovirus-mediated gene transfer of the RAP gene. As
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would be expected, in apoE knock-out mice, plasma 
cholesterol levels were not affected at all when mice 
were treated with the adeno-RAP construct. By contrast, 
in the apoE3-Leiden and apoE2 mouse (on an apoE- 
knock-out background), plasma levels went up threefold 
when the mice were infected with the adeno-RAP 
construct. This suggests that for both VLDL apoE2 and 
VLDL apoE3-Leiden, LRP is involved in their removal. 
The role of other receptors in VLDL clearance was 
examined using mice that were infected with an adeno­
virus containing a construct for the VLDL receptor. On 
day 5 after infection, plasma cholesterol levels were 
reduced more than 50% in both apoE2 and apoE3- 
Leiden mice, mainly accounted for by reduction in the 
VLDL and LDL fraction. These data indicate that both 
apoE2 and apoE3-Leiden can function as ligands for the 
VLDL receptor in vivo and suggest a possible role for 
the VLDL receptor gene and gene therapy for the 
treatment of familial dysbetalipoproteinemia.
In the first of two smaller sessions, focused on “Li­
poproteins and the Kidney,” Dr H.-J. Grone (Marburg) 
gave a lecture on the role of lipoproteins in nephrosis 
and glomerulosclerosis. He defined nephrosclerosis as a 
degeneration of proglomerular arteries and arterioles 
with consecutive glomerulosclerosis. Foam cells are not 
normally observed in nephrosclerosis, and arterial hy­
pertension has been thought to be a major causative 
factor of this disease. However, examination of human 
renal biopsies has revealed the presence of foam cells in 
the capillaries and the mesangium of the glomerulus. 
The following factors are associated with the develop­
ment of glomerulosclerosis: mechanical (arterial and 
glomerular hypertension), hormonal (endothelin, angio­
tensin II, vasoactive peptides), immunologic (immune 
complexes), and metabolic (hyperglycemia, hyperlipid­
emia). In a rat model, a synergism between arterial 
pressure and hyperlipidemia was observed. The extent of 
glomerulosclerosis in hyperlipidemic animals fed a high- 
fat, cholesterol-rich diet was enhanced in the clipped 
hypertensive kidney, whereas no glomerulosclerosis was 
seen in the unclipped hypotensive kidney. In cellular 
studies, human mesangial cells were found to have a 
much higher affinity for 0-VLDL than for LDL, and the 
maximal capacity for the uptake of 0-VLDL could be 
increased by the vasoactive peptides endothelin-1, an­
giotensin II, and platelet-derived growth factor (PDGF). 
Further experiments demonstrated that LDL could pro­
voke a significant but not pronounced increase in cellu­
lar DNA synthesis as measured by 3H-thymidine uptake. 
In the presence of PDGF, there was a pronounced 
synergistic induction of cell proliferation. He went on to 
describe experiments in the guinea pig in which LDL at 
a concentration of 50 jug/mL was found to induce the 
early expression genes c-fos and c-jun but not c-myc. 
Both LDL and /3-VLDL were also able to stimulate the 
expression of PDGF. Guineas pigs fed a fat-rich diet 
were found to have lipid deposition in the glomerulus. 
Animals treated with a low dose of lovastatin, which did 
not alter VLDL and LDL levels, showed reduced mes­
angial cell proliferation and sclerosis, presumably be­
cause of the inhibition of the prenylation of proteins 
involved in cell proliferation.
The monocyte is an essential cell for the development 
of glomerulosclerosis: myeloperoxidase is found in large 
amounts in the human kidney and, therefore, provides
the potential for the formation of hydroxychlorite and 
subsequent modification of LDL. With use of a Mab 
specific for hydroxychlorite-modified LDL, this modified 
lipoprotein could be demonstrated in biopsies from 
human kidneys. Furthermore, HOCL-modified LDL 
was shown to induce expression of cytokines such as IL-8 
in the human monocyte.
Dr J. Joles (Utrecht) discussed plasma lipoproteins 
and the development of glomerulosclerosis and renal 
disease in animal models. He posed the question as to 
whether glomerulosclerosis and atherosclerosis have a 
common pathogenesis and noted that individuals with 
homozygous familial hypercholesterolemia and severe 
premature atherosclerosis do not appear to be at in­
creased risk for renal disease. He suggested that rather 
than LDL, the triglyceride-rich lipoproteins chylomi­
crons, VLDL and IDL, are of primary importance in the 
development of glomerulosclerosis. Evidence for such a 
hypothesis comes from studies in an animal model, the 
analbuminemic rat. Male rats are generally more prone 
to developing renal disease than females. However, in 
the case of the analbuminemic rat, females are pro­
foundly hyperlipidemic and develop and
glomerulosclerosis after uninephrectomy. Male anulbu- 
minemic rats on the other hand are less hyperlipidemic 
and are more resistant to developing renal damage after 
uninephrectomy. The importance of triglyceride-rich 
lipoproteins in the pathogenesis of renal disease in this 
animal model was further substantiated through studies 
in the ovariectomized analbuminemic female rat. Ovari­
ectomy of female analbuminemic rats markedly de­
creased plasma triglyceride levels by lowering hepatic 
triglyceride secretion, leading to a profound and persis­
tent reduction in their hyperlipidemia. Animals that had 
been ovariectomized during the first 12 weeks did not 
develop proteinuria.
Dr J. Moorhead (London) presented investigations on 
the influence of cytokines and calcium channel blockers 
in the expression of LDL and scavenger receptors on 
human mesangial cells in culture. The mesangial cell is a 
multipotent cell that can both oxidize LDL and release 
cytokines. Tumor necrosis factor-«, transforming growth 
factor-/3, PDGF, and interleukin-1 (IL-1) were all found 
to stimulate LDL receptor expression in a dose-depen­
dent manner. Tumor necrosis factor-cv, PDGF, and IL-1 
also effectively induced scavenger receptor expression, 
but in contrast tumor growth factor-0 inhibited the
expression of this receptor. The induction of 
LDL receptor and the scavenger receptor by tumor 
necrosis factor-«, and PDGF as well as the induction of 
the LDL receptor by tumor growth factor-0 apparently 
require protein synthesis, as suggested by experiments in 
which cells were pretreated with cycloheximide. In con­
trast, the induction of the two receptor genes by IL-1 was 
not affected by cycloheximide. These results suggest that 
tumor growth factor-0 may protect human mesangial 
cells from lipid accumulation by stimulating LDL recep­
tor expression while at the same time inhibiting expres­
sion of the scavenger receptor. The second part of his 
talk was devoted to the influence of calcium channel
o n ession of the I in
mesangial cells. Calcium channel blockers are known to
course of glomerulosclerosis, but the mecha­
nism is still unclear. Human mesangial cells were, there­
fore, exposed to three kinds of calcium ehanne
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nifedipine, diltiazem, and verapamil. Northern blot anal­
ysis showed that all three calcium channel blockers could 
stimulate the expression of LDL receptor mRNA in a 
dose-dependent manner. LDL receptor promoter activ­
ity was also increased, whereas the stability of LDL 
receptor mRNA was unaffected. These results suggest 
that calcium channel blockers may reduce lipid deposi­
tion and oxidation by upregulating LDL receptor or 
regulating the downstream events in cellular degrada­
tion and efflux of LDL.
Dr F. Kronenberg (Innsbruck) discussed “Lp(a) and 
renal disease” and covered several clinical and metabolic 
aspects of this atherogenic lipoprotein. He first gave an
and genetics of Lp(a), 
the exclusive genetic control of Lp(a) plasma 
levels in the general population. These Lp(a) concentra­
tions are inversely correlated with a genetic size poly­
morphism of apo(a) because of a highly variable number 
of identical kringle 4 domains. Because elevated Lp(a) 
levels have been found to be associated with atheroscle­
rotic complications such as coronary heart disease and 
stroke, Lp(a) can be regarded as a genetically deter­
mined risk factor for those diseases. However, nonge- 
netic influences on Lp(a) plasma concentrations such as 
hormonal regulation and effects secondary to certain 
diseases such as renal insufficiency also occur. In the 
second part of his talk, he concentrated on the signifi­
cance of elevated Lp(a) plasma concentrations in pa­
tients with end-stage renal disease. He discussed the 
statistical problems associated with case-control studies 
on Lp(a). Because Lp(a) plasma concentrations show a 
skewed distribution in most populations and span a wide 
range, analysis of small sample groups (n<100) may lead 
to nonrepresentative results. Case-control studies fulfill­
ing the criteria n >  100 have consistently shown an Lp(a) 
elevation of between 30 and 100% in patients treated by 
hemodialysis or continuous ambulatory dialysis, higher
levels generally m latter group.
Prospective studies measuring Lp(a) before and after 
renal transplantation consistently showed a decrease in 
Lp(a) independent of the mode of immunosuppressive 
therapy. This together with the unchanged apo(a) phe­
notype pattern clearly demonstrated that the elevation 
of Lp(a) in renal patients has a nongenctic background 
and is caused by the disease itself. Next, he reported on 
arteriovenous differences in Lp(a). In a study of 100 
patients with normal renal function, Lp(a) concentra­
tions were lower in the renal vein than in the renal
consistent with extraction of Lp(a) from the 
circulation by the healthy human kidney. Three studies 
have reported the occurrence of apo(a) fragments with 
molecular weights ranging from 30 to 215 kDa in urine. 
These observations suggest that mechanisms other than 
glomerular filtration might be involved in the generation 
of urinary apo(a) fragments. The lecture ended with an 
overview on studies into the significance of Lp(a) as an 
atherosclerotic risk factor in renal disease. Only a few 
large studies are presently available linking Lp(a) to the 
high risk of atherosclerosis seen in these patients. There 
is evidence from some studies, however, that the apo(a) 
phenotype may be o f major importance for risk assess­
ment, at least in hemodialysis patients.
Dr T. Willnow (Berlin) presented recent data on the 
possible involvement of Gp330/megalin in developing
neural tissues. is a 600-kDa
receptor and a member of the still-growing LDL recep­
tor gene family. The receptor is expressed on the apical 
surface of the epithelial tissues of the lung, intestine, 
neuroectoderm, and the proximal tubules of the kidney, 
where it mediates the endocytic uptake of various mac­
romolecules including cholesterol-carrying lipoproteins. 
Megalin has been identified as the major autoantigen in 
an induced glomerular nephritis rat model (I-Ieymann 
nephritis). During embryonic development, megalin is 
expressed in the yolk sac, the amniotic ectoderm, and 
the neuroectoderm. To elucidate its physiologic role, 
megalin-delicient mice were constructed by gene-target­
ing. Homozygous-deficient animals are born alive but 
die perinatally. They suffer from severe developmental 
malformations of the forebrain that include fusion of the 
forebrain hemispheres, lack of olfactory bulbs, and a 
common ventricular system. Similar syndromes in hu­
mans and animals are caused by insufficient supply of 
cholesterol during development. Before the formation 
of the circulatory system, lipids are supplied to 
developing embryo by transport across the yolk sac and 
diffusion-dependent uptake by embryonic tissues. It was, 
therefore, proposed that megalin might be part of the 
maternal-fetal lipid transport system, mediating uptake 
of lipids and lipid soluble vitamins into the developing 
neuroepithelium.
Dr J. Nimpf (Vienna) 
studies on megalin and another target antigen in the 
Heymann nephritis model, RAP. This 40-kDa protein is 
related to several members of the LDL receptor family. 
In the chicken oocyte receptor model (OVR, which 
binds VLDL and vitellogenin), RAP and members of the 
LDL receptor family share a common immunologic
;s against ree cross-
reacted with OVR and other members of the LDL 
receptor family including LRP (LDL-receptor related 
protein) and megalin. The interaction of this antibody 
with OVR was comparable with the binding of physio­
logic ligands to this receptor: binding of the antibody was 
Ca~f- , was i u M' re I-
tions, and inhibited the binding of VLDL and vitellone- 
nin. By using recombinant fragments of RAP, the cross- 
reacting epitope could be localized to the car 
terminal end of this protein. After immunization of 
rabbits, anti-OVR antibodies arose at the same time as 
anti-RAP antibodies, indicating that the OVR-specilic 
activity was not caused by anti-idiotypic antibodies.c
These results suggest the existence of a common epitope 
on both proteins as well as on other members of the 
LDL receptor family and favor the model of cross-
reactive epitopes for 
nephritis.
Dr P. Tarugi (Modena) reported on the synthesis of 
apolipoproteins B and AI by the chicken kidney. This 
organ was seer*'
s o f ,, LDL, anti
s as 
relative
amounts of apoB and apoAI being about 50% of that 
produced by the liver. It could be shown immunohisto- 
chemieally that both proteins are primarily synthesized 
in proximal and distal convoluted tubules of the kidney 
cortex but not in collecting tubules. The high rate of  
renal apolipoprotein production in the chicken appears 
to be related to the direct uptake of intestinal lipids by 
the tubular epithelial cells via the renal portal system. 
Ten minutes after infusion of a ‘‘'C-cholesterol-contain-
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ing lipid emulsion into the terminal ileum, radioactivity 
was found in the kidney, suggesting that intestinal li­
poproteins are directly transported to the kidney via the 
caudal-mesenteric vein branch of the renal portal sys­
tem. These results suggest that chicken renal lipopro­
teins significantly contribute to the plasma lipoprotein 
pool.
In the session on “Causes and Consequences of the 
Metabolic Syndrome,” Dr E. Ferrannini (Pisa) gave a 
comprehensive overview on the different facets of the 
metabolic syndrome, limiting the discussion to data 
derived from human studies. He first showed that 
plasma insulin concentrations (fasting as well as postglu­
cose) display a skewed distribution in the general pop­
ulation (such as blood pressure or triglyceride levels). By 
using a statistical definition of hyperinsulinemia, there is 
a marked enrichment in the prevalence of NIDDM, 
hypertension, obesity, and dyslipidemia in the hyperin- 
sulinemic segment of the population in comparison with 
normoinsulinemic subjects. A  similar clustering is ob­
served when the analysis is limited to a nonobese cohort. 
In studies in which insulin sensitivity has been measured 
directly (by the insulin clamp technique), an inverse 
relationship is found between insulin sensitivity and 
insulin levels. Although this relation indicates that insu­
lin levels are a proxy for insulin action, the scatter of the 
association is such that the two variables cannot be used 
interchangeably.
The relationship between insulin and glucose levels 
characteristically takes the form of an inverted U, indi­
cating that increasing degrees of glucose intolerance are 
associated with increasing insulin resistance up to a 
breakpoint (around 8 mM), after which /3-cell function 
fails to keep up with insulin resistance and progressive 
fasting hyperglycemia develops. This biphasic function is 
observed both cross-sectionally and longitudinally; thus, 
in long-term follow-up studies, both insulin resistance 
and /3-cell impairment are independent predictors of 
NIDDM.
Another metabolic change consistently associated 
with hyperinsulinemia and insulin resistance (in both 
diabetic and nondiabetic subjects) is an increased con­
centration of fasting and postprandial nonesterified fatty 
acid (NEFA). In a population-based survey (the San 
Antonio Pleart Study), NEFA cluster with almost all the 
features of the metabolic syndrome. An excess of endog­
enous or exogenous NEFA can lead to impaired periph­
eral glucose uptake (by substrate competition) as well as 
enhanced gluconeogenesis and endogenous glucose re­
lease (as a result of increased uptake and oxidation of 
NEFA in the liver). Conversely, insulin resistance of 
lipolysis (as occurs in lean NIDDM patients) leads to 
excessive hydrolysis of triglycerides and availability of 
NEFA for oxidation. Thus, raised NEFA can be at the 
same time the cause and the consequence of insulin 
resistance. Increased flow of NEFA to the liver also 
triggers VLDL-triglyceride synthesis, which is associated 
with the increased formation of atherogenic, small dense 
LDL particles. This pattern (pattern B) of LDL particle 
distribution has been shown to be independently associ­
ated with insulin resistance in nondiabetic individuals.
A positive correlation between hyperinsulinemia/insu- 
lin resistance and elevated blood pressure has been 
found in many population studies, including children 
and adolescents. A family history of NIDDM is associ-
ated with a higher prevalence of hyperinsulinemia and 
hypertension (an example of co-tracking). In nondia­
betic subjects, higher glucose levels are a good predictor 
for the development of hypertension 18 years later. 
Among lean hypertensives, a higher frequency of im­
paired glucose tolerance can be observed than among 
normotensives. Overall, high insulin levels in normal 
subjects have been shown to predict the three main 
components of the insulin resistance syndrome, i.e., 
NIDDM, hypertension, and the hypertriglyceridemia/ 
low HDL-cholesterol couple.
The list of cardiovascular risk factors included in the 
metabolic syndrome increases steadily. New members 
include abdominal obesity, increased plasminogen acti­
vator inhibitor-1 and fibrinogen levels, micro-albumin­
uria, hyperuricemia, and raised Na/Li counter transport 
and cytosolic calcium levels. For some of these associa­
tions, the mechanisms have been elucidated. Thus, in 
healthy as well as in hypertensive subjects, insulin causes 
an increased tubular reabsorption of uric acid in cou­
pling with its antinatriuretic effect. Although insulin 
antinatriuresis can contribute to raising or maintaining 
high blood pressure, the antiuricosuric effects of insulin 
might relate to the hyperuricemia that is frequently 
observed in NIDDM or essential hypertension. NIDDM  
patients with hypertension are more insulin-resistant 
than normotensive patients, and typically, their blood 
pressure is salt-sensitive. Insulin also lowers intracellular 
calcium concentrations in sensitive tissues. In smooth 
muscle cells, this translates to lower tension develop­
ment and sensitivity to agonists. In platelets, a blunted 
calcium spike in response to agonists corresponds to 
decreased platelet aggregation. Platelets from insulin-re­
sistant subjects fail to reduce intracellular calcium in 
response to insulin and are more prone to aggregation. 
The mechanism(s) underlying the association of insulin 
resistance with microalbuminuria have yet to be 
described.
The insulin resistance syndrome is not a disease but 
rather a risk syndrome. Because many, if not all, of its 
components are significant, independent predictors of 
atherosclerotic cardiovascular disease, the syndrome can 
be viewed as a complex of physiologic interrelations, 
which transduces the impact of environmental influences
(stress, smoking, alcohol, etc) into
mechanisms. Against a background of genetic predispo­
sition, clinical ases
ancl NIDDM — develop, eventually leading to cardiovas­
cular disease.
Dr P. Arner (Huddinge) reported from studies on 
gender differences in visceral fat 
relation to metabolic complications in obesity. Although 
abdominal fat constitutes only about 10% to 15% of the 
total fat mass, it is metabolically extremely active and 
fatty acids released directly reach the liver via portal 
vein. Omental fat cells recovered during elective surgery 
from 29 obese males and 34 obese females showed a 
twofold higher release of fatty acids and glycerol in male 
tissue because of 12 times higher lipolytic /3-3-acIreno- 
ceptor sensitivity and 17 times lower antilipolytic a-2
adrenoceptor sensitivity. Also, induced by
agents acting at the PKA or hormone-sensitive lipase 
level were twofold increased in males over females. The 
observation of increased ability of cAMP to activate
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hormone-sensitive lipase in males cannot be explained 
up to now. Studies on totally removed omental fat tissue 
(=«1-2 kg), which was done in addition to gastric banding 
procedures, showed that cathecholamine-induced fatty 
acid release from total omentum was 2 times more rapid 
in men than in women. These findings explain dimin­
ished features of the metabolic syndrome in women 
compared with men with the same degree of obesity.
Overproduction of VLDL, a feature of FCH, is also 
associated with insulin resistance. Dr A. Stalenhoef and 
colleagues (Nijmegen) investigated directly 
sensitivity in nonobese patients with FCH 
nonailected first-degree relatives, using the 
hyperinsulinemic clamp technique. During the clamp, 
forearm blood flow was measured by venous 
plethysmography. The patients and relatives had normal 
glucose tolerance according to an oral 75-g glucose 
tolerance test. Mean whole body glucose uptake and 
insulin sensitivity index were lower in the FCH patients 
than in the nonaffected subjects. The forearm blood flow 
increased only in the nonaffected subjects. This study 
demonstrated that nonobese subjects with FCH are, on 
average, insulin-resistant, which may partly be explained 
by a decreased insulin-induced vasodilation in skeletal 
muscle.
Dr J. Reckless (Bath) studied the concentration and 
composition of lipoprotein subfractions (fasting and 
postprandially after a 75-g fat load) in patients with and 
controls. Glucose, insulin, and NEFA were measured 
and insulin resistance and jS-cell function calculated. 
The data clearly reflected a relative insulin lack, with 
increased NEFA flux, decreased catabolism of triglycer­
ides (TG)-rich lipoproteins, TG enrichment o f all frac­
tions and an increased proportion of large VLDL, an 
increase in small LDL (Sf 3-6), and reduction of HDL
insulin resistance in healthy middle-aged men, who were 
chronic smokers or users of nicotine-containing chewing 
gum. Smokers were insulin-resistant as measured with 
the clamp technique; they had impaired clearance of TG 
after a meal, despite normal fasting lipid levels. The 
proportion of small, dense LDL was increased, as was 
postheparin hepatic lipase activity. The degree of insulin 
resistance was correlated to smoking habits. The degree 
of insulin sensitivity and HDL cholesterol and apoAII
8 weeks after'i/\ n  T iw increai
smoking cessation. Chronic nonsmoking users of nico-
resistant,
the degree of which was positively correlated to nicotine 
consumption as determined by plasma cotinine levels. 




•ols. He reported abnormal TG clearance in the 
:s, which was dependent on fasting TG levels and
Dr B. Eliasson investigi variables of
mass index but independent of their apoE pheno­
type. Several patients displayed mutations in the LPL 
gene. Postprandial insulin levels were increased in 8 of 
14 patients and correlated with body mass index.
The 20th Annual Meeting of the European Lipopro­
tein Club was held September 8 to 11, 1997, in Tutzing, 
Germany. It began with the Anniversary Lectures on 
Recent Developments in Lipoprotein Research, fol­
lowed by sessions on: 1) Lipoprotein Receptors (Old 
and New); 2) Significance of Lipoprotein Heterogeneity 
(Metabolic and Pathological Aspects); 3) Novel Meth­
odologies for Lipoprotein Research. For information 
contact Prof. Guido Franeeschini, Secretary ELC, Cen­
tro E. Grossi Paoletti, Institute of Pharmacological 
Sciences, Via Balzaretti 9, 20133 Milan, Italy. Fax: 
39/2/29007018. E-mail lTancescCfiHsfunix.farma.unim
